Yatharth group gets ₹43.8 Cr in final tax demands plus ₹15.9 Cr interest; appeals next, no provision booked
Final assessment orders cover the parent and two subsidiaries, reaching back to AY 2014-15. The ₹59.7 Cr total is about 0.6% of market cap — and 1.3× last quarter's profit.
MID-CAP
by market cap ≈ ₹9,311 Cr
₹43.80 Cr
across three group entities
₹15.94 Cr
as stated in the orders
0.64%
₹59.74 Cr of ≈ ₹9,311 Cr
₹45.42 Cr
consolidated — the demand is ~1.3× this
₹966.30
Sep 11 · −5.7% from 52-week high
Three final assessment orders, one disclosure
Final income-tax assessment orders received; company and subsidiaries to appeal
Yatharth Hospital disclosed that it and two subsidiaries — AKS Medical & Research Centre Private Limited and Ramraja Multispeciality Hospital & Trauma Centre Private Limited — received final assessment orders from the Deputy Commissioner of Income Tax, Central Circle-28, Delhi. Aggregate demands: ₹29.66 Cr plus ₹11.42 Cr interest on the company (AY 2014-15 to AY 2024-25), ₹8.50 Cr plus ₹2.48 Cr on AKS (AY 2022-23 to AY 2024-25), and ₹5.64 Cr plus ₹2.04 Cr on Ramraja (AY 2023-24). All three are in the process of filing appeals before the CIT (Appeals). The filing states no provision is presently required.
Read:This turns a long-running tax matter into a quantified number: ₹59.74 Cr including interest, roughly 0.6% of market cap but more than one quarter of consolidated net profit. The appeals now determine how much of it ever hits the accounts.
BSE filing, Sep 14 — Developments in Income Tax ProceedingsThe mechanics, as the filing describes them: with the orders passed, "the assessment proceedings for the assessment years mentioned above stand concluded" — the assessing officer's stage is over. On the advice of external tax consultants, the company and both subsidiaries are in the process of filing appeals before the CIT (Appeals). The filing is titled "Favourable Developments in Income Tax Proceedings" and presents itself as a furtherance of earlier intimations on the matter; what the text offers in support of that framing is the conclusion of the assessment stage and the company's stated confidence of substantial relief on appeal. The demands themselves are new, final and quantified.
Demands and interest as stated in the Sep 14 filing; row and column totals computed. AKS and Ramraja are subsidiaries of the company, per the filing.
Scale matters here. Against a market cap of roughly ₹9,311 Cr (9.64 Cr shares × the ₹966.30 close of Sep 11), the full ₹59.74 Cr is about 0.64% — small at the balance-sheet-of-the-market level. Against the P&L it is not small: it exceeds the ₹45.42 Cr of consolidated net profit Yatharth reported for Q1 FY27, and is close to one quarter's pre-tax profit (₹61.21 Cr). Because the company's stated view is that no provision is presently required, none of this amount is reflected in the reported numbers. The filing reached the exchange at 15:02 IST on September 14, late in that day's session; the price series available for this report runs through September 11, so the market's first response is not yet in the data.
Based on internal assessment, the Company is confident of obtaining substantial relief in the appellate proceedings and consequently a significant reduction in the aforesaid demands. Accordingly, the Company is of the view that no provision is presently required in the financial statements in this regard.
— Yatharth Hospital — BSE filing, September 14, 2026
A crowded five weeks — results, a stake rumour, and now a fund-raise agenda
Same day, after close: board to consider fund-raising on September 17
Forty-three minutes after the tax disclosure — and fifteen minutes after the session closed — Yatharth filed notice of a board meeting on Thursday, September 17, to discuss growth plans and a proposal to fund them by raising debt, a rights issue, preferential allotment, qualified institutions placement, or other permissible modes, through equity shares, warrants, debt securities or convertibles.
Read:The intimation lists every permissible route and commits to none, so instrument, size and pricing are all open until the outcome. Filed after the 15:30 close, it can first be traded on September 15.
BSE filing, Sep 14 — Board Meeting IntimationThe two September 14 filings land on a stock that has had an eventful run. On August 10 the company reported Q1 FY27: consolidated revenue of ₹392.65 Cr, net profit of ₹45.42 Cr, a press release calling revenue growth a record 51% YoY, and a first interim dividend of ₹0.50 per ₹10 share. On August 28, Moneycontrol carried a report headlined "Aster, Advent eye controlling stake in Yatharth Hospital, says report; shares rise 4.5%"; the company's exchange reply confirmed there was no information requiring disclosure under Regulation 30, while noting that it "keeps exploring various strategic opportunities" as part of its business strategy. The stock rose 17.2% between the August 21 and August 31 closes and touched its 52-week adjusted high of ₹1,024.75 on August 28.
The tape shows a stock consolidating below its high, not one under pressure. From the August 21 close of ₹855.15 to the August 31 close of ₹1,001.90 — a stretch spanning the results digestion and the stake-interest report — the stock gained 17.2% on visibly heavier volumes (August 24 alone traded 11.6 lakh shares against a few-lakh norm earlier in the month). Since then it has drifted between roughly ₹962 and ₹995, closing September 11 at ₹966.30, 5.7% below the 52-week adjusted high. The tax and fund-raise filings of September 14 will get their first full trading verdict in the sessions that follow this data.
The earnings context cuts both ways. Revenue has climbed five straight quarters, from ₹257.77 Cr to ₹392.65 Cr, with operating margins in the 23–25% band throughout — this is a business compounding fast enough that a one-time ₹59.74 Cr outflow, if it ever came to that, would be absorbed by about one and a third quarters of current profit. But that is the inference, not the filing: what the filing states is that the demands exist, that appeals are being filed, and that in the company's view no provision is required. Until the CIT (Appeals) rules, the gap between ₹59.74 Cr and whatever survives appeal is unquantifiable from the disclosure — the company predicts "substantial relief" but attaches no number to it.
The filings that would change this picture
CIT (Appeals)
Confirmation that the appeals are lodged, and any order granting relief, a stay, or part-payment terms. The filing gives no timeline for the appellate process.
Sep 17 board meeting
The fund-raise outcome — instrument (debt, rights, preferential, QIP), size and pricing are all open in the intimation. A preferential allotment or QIP would also name the investors.
Q2 FY27 results
Whether the no-provision stance holds and how the demands are presented in the statements — any change in that treatment would show up here first.
The tape from Sep 15
The tax disclosure hit at 15:02 IST on Sep 14 and the fund-raise notice after the close; the first sessions after this report's price data will show how the market weighs the two together.
What is established: three final assessment orders totalling ₹43.80 Cr in demands and ₹15.94 Cr in interest, covering the parent back to AY 2014-15 and two subsidiaries over shorter windows; appeals in progress; no provision booked. What is not established: how much of it survives appeal, how long that takes, and whether any deposit is required along the way — the disclosure is silent on all three.
The exposure is bounded and modest against the company's ₹9,311 Cr market value, but material against a single quarter's profit, which is why the provision question is the one to track. The same board that discloses confidence of substantial relief meets on September 17 to consider raising funds for growth. Two processes, two calendars — the appellate one is measured in filings, and the next scheduled date is Thursday.
Informational and educational content only. Not investment advice.